The latest biotech news

Cytimmune Sciences nanoparticles red recognizing entering and accumulating in cancer cells

News and Trends 23 Aug 2022

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

Researchers from Cytimmune Sciences, a clinical-stage biotech company, have presented new data on the company’s novel cancer nanomedicines. The presentation took place at the Cytokine Drug Development Conference held in Boston, Massachusetts, late last month. David Oarr, Cytimmune’s president, participated in the event’s opening panel to discuss the current clinical status and future anticipated progress […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

BioInnovation Institute launches new program and takes on four companies

The BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating life science research, says four companies have joined its new Venture House program. Formerly known as Creation House, the new Venture House program consists of the same 18-month long program with a risk-free convertible loan of €1.3 million ($1.3 million). […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Parkinson’s Foundation and Parkinson’s UK partner to drive drug development

The Parkinson’s Foundation and Parkinson’s UK, which funds research and provides support for people with Parkinson’s disease (PD), have announced a new international strategic partnership to boost investment in research on new treatments for PD, which affects 10 million people worldwide. Over the next three years, the Parkinson’s Foundation will invest a minimum of $3 […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Gate Neurosciences emerges from stealth to tackle CNS diseases

Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

In Depth 23 Aug 2022

Company’s 3D microchip gives mechanistic insights into human brain

A microchip that allows scientists to study the complexity of 3D cellular networks at unrivaled scale and precision has been added to 3Brain AG’s brain-on-chip portfolio. In collaboration with Swiss precision manufacturing experts, CSEM, 3Brain AG made the announcement today (August 22). The cell-electronic interface technology will also allow scientists to gain novel mechanistic insights […]

August 23, 2022 - 5 minutesmins - By Liza Laws

News and Trends 23 Aug 2022

180 Life Sciences announce enrollment of the first patient in frozen shoulder treatment trial

The first patient has been enrolled on a clinical trial to evaluate anti-tumor necrosis factor for patients with early-stage, pain predominant frozen shoulder. 180 Life Sciences, a clinical-stage biotechnology company made the announcement yesterday (August 22). James Woody chief executive officer of 180 Life Sciences, said: “Recruiting the first patient for the trial of anti-TNF […]

August 23, 2022 - 2 minutesmins - By Liza Laws

Alume Biosciences announces first patient dosed with ALM 488

News and Trends 23 Aug 2022

Alume Biosciences progressing with fluorescence study in patients undergoing head and neck surgery

Alume Biosciences, Inc. says the first patient has been dosed in a phase 3 pivotal study of ALM-488, a peptide-dye conjugate designed to highlight nerves with fluorescence in real time during surgery. “The successful initiation of this phase 3 pivotal study is another major milestone for Alume Biosciences. It marks the final phase of clinical […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Constructive Bio launches with $15M seed investment to re-engineer biology

A biotech company has launched in the UK after securing a deal that includes intellectual property re-engineering biology by creating new classes of enzymes, pharmaceuticals and biomaterials. Constructive Bio has completed a $15 million (€15 million) seed round and gained an exclusive license from the Medical Research Council to intellectual property (IP) developed by Professor […]

August 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Aug 2022

Ocelot Bio receives FDA Orphan Drug Designation for lead candidate for treatment of hepatorenal syndrome

Ocelot Bio, Inc., a clinical-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead candidate OCE-205 for the treatment of hepatorenal syndrome. Ocelot Bio is currently enrolling patients in a phase 2 clinical trial of OCE-205 in hepatorenal syndrome with acute kidney injury (HRS-AKI), […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Institute for Bioscience and Biotechnology Research awarded $6.9M to work on hepatitis C vaccine

The National Institute of Allergy and Infectious Disease (NIAID) has awarded a $6.9 million grant to researchers at the Institute for Bioscience and Biotechnology Research (IBBR) to design a vaccine to combat the virus that causes hepatitis C. Hepatitis C is an illness that affects an estimated 71 million people worldwide. Hepatitis C Virus (HCV) […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Aug 2022

Drug to treat rare kidney disease to be reviewed by EMA

The European Medicines Agency (EMA) has agreed to review a conditional marketing authorization (CMA) application for a drug to treat a rare kidney disorder. The news was announced today (August 21) by CSL Vifor and Travere Therapeutics Inc, and, if approved, the companies say sparsentan will address a significant unmet need in treating IgA nephropathy […]

August 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Aug 2022

EpiVario looks to biotech for PTSD treatment

Emerging U.S. biotech company EpiVario, Inc. has highlighted preclinical research findings that could lead to a treatment approach for post-traumatic stress disorder (PTSD). Published in Proceedings of the National Academy of Sciences (PNAS), and co-authored by the academic co-founders of EpiVario, the study demonstrates that fear memories can be controlled through the enzyme acetyl-CoA synthetase […]

August 22, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

BioInnovation Institute launches new program and takes on four companies

Parkinson’s Foundation and Parkinson’s UK partner to drive drug development

Gate Neurosciences emerges from stealth to tackle CNS diseases

Company’s 3D microchip gives mechanistic insights into human brain

180 Life Sciences announce enrollment of the first patient in frozen shoulder treatment trial

Alume Biosciences progressing with fluorescence study in patients undergoing head and neck surgery

Constructive Bio launches with $15M seed investment to re-engineer biology

Ocelot Bio receives FDA Orphan Drug Designation for lead candidate for treatment of hepatorenal syndrome

Institute for Bioscience and Biotechnology Research awarded $6.9M to work on hepatitis C vaccine

Drug to treat rare kidney disease to be reviewed by EMA

EpiVario looks to biotech for PTSD treatment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!